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We have used a novel variant of the human oestrogen receptor (ER)-positive MCF-7 cell line, TMX2-28, as a model to study breast
cancer. TMX2-28 cells show no detectable levels of mRNA or protein expression for the ER and express basal cytokeratins (CKs) 5,
14, and 17. cDNA microarray comparison between TMX2-28 and its parent cell line, MCF-7, identified 1402 differentially expressed
transcripts, one of which was, phospholipase D1 (PLD1). Using real-time RT–PCR, we confirmed that PLD1 mRNA levels are 10-
fold higher in TMX2-28 cells than in MCF-7 cells. We next examined PLD1 expression in human breast carcinomas. Phospholipase
D1 mRNA levels were higher in breast tumours that expressed high-mRNA levels of basal CKs 5 and/or 17, but PLD1 mRNA
levels were not significantly higher in ER-negative tumours. Phospholipase D1 protein was overexpressed in 10 of 42 (24%) breast
tumours examined by IHC. Phospholipase D1 was overexpressed in 6 of 31 ER-positive tumours and 4 of 11 ER-negative tumours.
Phospholipase D1 was overexpressed in three of the four tumours that showed high CK5/17 expression. Five PLD1-positive tumours
were negative for phospho-Akt expression, but positive for phospho-mammalian target of rapamycin (mTOR) expression. The other
five PLD1-positive breast tumours showed positive expression for phospho-Akt; however, only two of these cases were positive for
phospho-mTOR. In this study, we report that PLD1 and phospho-mTOR are coexpressed in a subset of phospho-Akt-negative
breast carcinomas.
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Phospholipase D1 (PLD1) is a phospholipid-metabolising enzyme
that catalyses the hydrolysis of phosphatidylcholine to phosphatidic
acid (PA) and choline, consequently activating a second messenger
signalling cascade consisting primarily of PA (Foster and Xu, 2003).
Phospholipase D1 is activated by upstream mitogens and is
dependent on the inositol phospholipid, phosphatidylinositol
(PI)-4,5-bis-phosphate (PIP2), for its complete activation. Phos-
pholipase D1 is involved in various cellular functions, including
vesicle trafficking, cell proliferation, and cell-cycle regulation
(Foster and Xu, 2003). Elevated PLD1 activity is associated with
cells that have high-tyrosine kinase activity (Joseph et al, 2001), and
increased PLD1 activity has been shown to generate survival
signals, causing cells to evade apoptosis (Zhong et al, 2003).
The mammalian target of rapamycin (mTOR) is a protein kinase
that controls the phosphorylation activity of several downstream
effectors and it is generally thought that the serine/threonine
kinase, Akt, is the primary driver of mTOR activation (Schmelzle
and Hall, 2000; Carraway and Hidalgo, 2004; Thomas, 2006).
Additionally, in response to mitogenic signals, the second
messenger PA binds to and activates mTOR by interacting with
the domain of mTOR that is also targeted by rapamycin (Fang
et al, 2001; Chen and Fang, 2002). It has been reported that PA is
sufficient to activate downstream mTOR effectors, and that PLD1
activates the PA/mTOR pathway controlling cell size and growth
(Fang et al, 2003). Mammalian target of rapamycin, in its role of
regulating protein translation and controlling cell growth, has been
implicated in cancer progression (Schmelzle and Hall, 2000;
Ruggero and Pandolfi, 2003), and several analogues of rapamycin,
a natural mTOR antagonist, are in clinical trials for various
cancers, including advanced and oestrogen receptor (ER)-depen-
dent breast cancer (Carraway and Hidalgo, 2004).
ER expression level in tumours has been the most important
clinical diagnostic parameter for breast cancers for the past 30
years (Osborne, 1998). In recent years, several researchers have
used cDNA microarray technology to identify a molecular portrait
or gene expression signature of breast cancers that correlates with
clinical outcome (Perou et al, 2000; Sorlie et al, 2001; Abd El-
Rehim et al, 2004). These studies have shown that breast tumours
can be subgrouped based on their cytokeratin (CK) expression
profile. Luminal-like breast tumours express (CKs) 8 and 18,
whereas basal-like tumours express CKs 5, 17 and/or 14 and are
often associated with a poor clinical outcome for the patient. We
used an ER-negative variant of the MCF-7 cell line, TMX2-28
(Fasco et al, 2003), which shows characteristics relevant to basal-
like tumours, as a model to study this aggressive subset of breast
cancers. TMX2-28 cells maintain a similar epithelial morphology
to MCF-7 cells and have not undergone epithelial–mesenchymal
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stransition. However, TMX2-28 cells are highly invasive compared
to MCF-7 cells as determined by their ability to invade through a
Matrigel layer (Gozgit et al, 2006). cDNA microarray comparison
of MCF-7 cells and TMX2-28 cells identified the overexpression of
PLD1 in the TMX2-28 cell line. Recently, Chen et al (2005) showed
that PLD1 and phospho-Akt are inversely expressed in a small
subset of breast cancer cell lines. The authors reported that
MDA-MB-231 cells have high-PLD1 activity, which is responsible
for promoting mTOR-dependent survival signals in these breast
cancer cells that do not express active PI3K/Akt survival signals.
Likewise, MDA-MB-435S cells have low levels of PLD1 activity and
are dependent on PI3K/Akt survival signals. The results from Chen
and colleagues are intriguing and in this study, we have used
clinical tissues to evaluate the expression of PLD1 with phospho-
Akt and phospho-mTOR in breast carcinomas to help facilitate
patient selection for mTOR-targeted therapies. We show that PLD1
is expressed in a subset of phospho-Akt-negative tumours that
maintain phospho-mTOR expression.
MATERIALS AND METHODS
Cell culture
TMX2-28 cells were kindly provided by Dr John Gierthy
(Wadsworth Center). MCF-7 cells were purchased from the American
Type Culture Collection (ATCC), and 184, 184A1, and 184AA2 cell
lines were a generous gift from Dr Martha Stampfer (Ernest
Orlando Lawrence Berkeley National Laboratory). Cell cultures
were maintained in complete growth medium and subcultured
according to the appropriate manufacturer’s/supplier’s protocols.
TMX2-28 and MCF-7 cells were grown in Dulbecco’s modified
Eagle’s medium (without phenol red) supplemented with 5%
cosmic calf serum (Hyclone, Logan, VT, USA), 2.0mML-glutamine,
0.1mM nonessential amino acids, 10ngml
 1 insulin, 100Uml
 1
penicillin, and 100mgml
 1 streptomycin (referred to as DC5).
Cell lines 184, 184A1, and 184AA2 were cultured according to
Dr Martha Stampfer’s protocol as posted on her website (http://
www.lbl.gov/LBL-Programs/mrgs). Cell cultures were maintained
in a 371C humidified incubator with either 5% CO2 for TMX2-28
and MCF-7 cells or 2% CO2 for all 184 cells.
Human tissue specimens
All tissue specimens (frozen-breast tumours, n¼30; formalin-
fixed, paraffin-embedded (FFPE) breast tumours, n¼46; and FFPE
tissues from reduction mammoplasty, n¼10) were retrieved from
Baystate Medical Center, Department of Surgical Pathology, and
were identified numerically, maintaining patient anonymity.
Clinical pathology reports accompanied all cases, providing data
on tumour type, histological grade, tumour size, stage, hormone
receptor, and HER2 expression status. IRB approval for this study
was obtained from Baystate Medical Center. All 76 breast tumour
samples were from primary breast carcinomas.
RNA purification
RNA was isolated from cell cultures during exponential growth
phase (70–80% confluence). Cells were washed two times with
PBS, and RNA was isolated with TRI Reagent (Molecular Research,
Cincinatti, OH, USA) according to the manufacturer’s protocol.
Isolated RNA was further purified using Qiagen RNeasy kit with
on-column DNase digestion (Qiagen, Valencia, CA, USA). Tissue
from frozen-breast carcinomas was sectioned to be not thicker
than 0.5cm, and immediately placed in prechilled RNA Later-Ice
(Ambion, Austin, TX, USA) and incubated until processing 24h
later. Tissue samples were weighed, and then sectioned with a
scalpel, and 20–30mg were homogenised using the Tissue-Tearor
(BioSpec Products, Bartlesville, OK, USA). RNA was isolated using
the Qiagen RNeasy Fibrous Tissue kit (Qiagen), which includes a
10min proteinase K digestion following homogenisation. All RNA
samples were quantified by measuring the absorbance at 260nm
with the GeneQuant (Amersham Biosciences, Piscataway, NJ,
USA), and RNA quality was assessed by gel electrophoresis.
cDNA microarray
To compare TMX2-28 to MCF-7 cells at the genomic level, we
performed global gene-expression analysis by cDNA microarray
technology. TMX2-28 and MCF-7 cells were grown for 48h in
charcoal/dextran-treated fetal bovine serum (FBS, Hyclone), and
RNA was isolated as described above when cells reached 80%
confluence. The integrity of the RNA was evaluated by gel
electrophoresis and sent to the Affymetrix Genechip Resource in
the Keck Biotechnology Resource Laboratory at Yale University
(New Haven, CT, USA). RNA was then tested with the Agilent 2100
Bioanalyzer, and global gene expression was evaluated on the
Affymetrix Human Genome U133 Plus 2.0 Array, consisting of
over 47000 transcripts, according to the Affymetrix Genechip
Resource standard operating procedures.
Real-time RT–PCR
Real-time RT–PCR was performed as described previously (Gozgit
et al, 2004). RNA (75ng) samples were reverse transcribed and
amplified using the One-Step RT–PCR kit (Qiagen) in the Roche
Light Cycler (Roche Applied Sciences, Indianapolis, IN, USA).
Generation of amplified products was monitored over 45 PCR
cycles by fluorescence of intercalating SYBR Green. Gene-specific
primers and 10-fold dilutions of RNA were used to create a
standard curve for each gene, which was stored for later
quantification of relative mRNA levels with the Roche Light Cycler
software. The mRNA levels were normalised to mRNA levels of
hypoxanthine ribosyltransferase (HPRT) as described previously
(de Kok et al, 2005).
The following gene-specific primers were designed using
Primer3 (Rozen and Skaletsky, 2000): PLD1 NM_002662
AATCGTTGGAGGTTGGACTG (sense, nt 1220), AGACGGTGGAT
GACACATGA (antisense, nt 1406); CK5 NM_ 000424 CAACC
CACTAGTGCCTGGTT (sense, nt 41) ATAGCCACCCACTCCAC
AAG (antisense, nt 267); CK14 NM_000526 TTCTGAACGAGA
TGCGTGAC (sense, nt 909), GCAGCTCAATCTCCAGGTTC (anti-
sense, nt 1097); CK17 NM_000422 GCTGCTACAGCTTTGGCTCT
(sense, nt 224) TCACCTCCAGCTCAGTGTTG (antisense, nt 341);
CK8 NM_002273 TGAGGTCAAGGCACAGTACG (sense, nt 847),
TGATGTTCCGGTTCATCTCA (antisense, nt 1007); CK18
NM_000224 CACAGTCTGCTGAGGTTGGA (sense, nt 892),
GAGCTGCTCCATCTGTAGGG (antisense, nt 1055) CK19
NM_002276 TGAGTGACATGCGAAGCCAATAT (sense, nt 799),
GCGACCTCCCGGTTCAAT (antisense, nt 901); CK20 NM_002276
TCCCAGAGCCTTGAGATAGAACTC, GTTGGCTAACTGGCTGCT
GTAAC (received from Dr Fasco, Wadsworth Center); HPRT
NM_000194 ACCCCACGAAGTGTTGGATA (nt 587, sense), AAG
CAGATGGCCACAGAACT (nt 834, antisense); and ERa (Fasco
et al, 2003).
Tissue microarray and immunohistochemistry
Two tissue microarrays (TMAs) were designed with 46 FFPE breast
carcinomas in which haemotoxylin and eosin-stained sections
were used to identify the infiltrating carcinoma cells. Three 0.8mm
diameter cores were extracted from each donor block and re-
embedded into a recipient paraffin-block containing holes spaced
0.8mm apart. Four-micrometre sections were placed on charged
slides, deparaffinised in xylene, and re-hydrated in graded
ethanols. Slides were rinsed with H2O and incubated in Citra Plus
Buffer (BioGenex, San Ramon, CA, USA) under the following
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sconditions for antigen retrieval: microwaved for 3min, cool 1min,
heated at 981C for 10min, and cooled for 20min. Immuno-
histochemistry (IHC) was performed on the DakoAutostainer
(Carpinteria, CA, USA) using Dako Envision Plus labelled
polymer-HRP reagents. Negative controls (no primary antibody)
were included for each tissue section. Primary antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA):
PLD1 (1:20, clone F-12); Dako (Carpinteria, CA, USA): CK5 (1:50,
clone D5/16 B4) and CK17 (1:25, clone E3); Cell Signaling
Technology (Danvers, MA, USA): phospho-Akt (1:25, no. 9277
and no. 3787, phospho-mTOR (1:25, no. 2971), and phospho-
p70S6K (1:100, 9277). Scoring for the two antibodies for phospho-
Akt showed B90% consistency; however, some tumours were
scored positive when only one antibody showed staining.
Immunoreactivity was scored by a pathologist (CN Otis) at two
separate times, and intravariability observation was o10%.
Immunohistochemistry sections were examined for overall stain-
ing intensity and assigned a numerical score, where 0¼negative
staining, 1¼weak or basal level, 2¼moderate, and 3¼strong
staining. A score of moderate or strong expression is considered
overexpressed. Owing to inadequate tissue samples from four
tumours represented on the TMA, PLD1 expression was evaluated
in only 42 of the 46 tumours; therefore, all other IHC analyses were
limited to these 42 cases. Immunohistochemistry analysis of tissue
specimens from reductive mammoplasty was performed on
individual tissue sections.
Western immunoblotting
Cell lysates were collected in SDS buffer (1% SDS, 0.06 M. Tris–
HCl, 10% glycerol), and protein concentrations were determined
using the BCA Protein Assay kit (Pierce, Rockford, IL, USA).
Protein lysates (10mg) were mixed with NuPage sample buffer and
reducing agent (Invitrogen, Carlsbad, CA, USA), and then heated
at 701C for 10min. Protein lysates were then separated on a 10%
Tris–HCl polyacrylamide gel (BioRad, Hercules, CA, USA) using
the Min-Protein 3 cell (BioRad) according to the manufacturer’s
protocol. Separated proteins were transferred to an Immuno-Blot
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Figure 1 Phospholipase D1 (PLD1) is overexpressed in the aggressive, oestrogen receptor (ER)-negative variant of MCF-7 cells, TMX2-28. (A) Cell
cultures were grown to subconfluence, and RNA and protein were purified. Oestrogen receptor-a mRNA expression was determined by real-time
RT–PCR (bottom), and protein expression was determined by western immunoblotting (top). Experiments were repeated two times; the bottom panel
shows the mean and s.d., and the top panel shows a representative image from one experiment. (B) Cell-cycle analysis was determined by propidium iodine
staining and FACS analysis. The mean and s.d. from two experiments are shown. The per cent of TMX2-28 cells in each phase of the cell cycle differed
significantly from the per cent of MCF-7 cells in the same phase (Po0.05). (C) Total RNA was isolated from cell cultures, and mRNA levels were
determined by real-time RT–PCR. Data for each cell line are normalised to hypoxanthine ribosyltransferase (HPRT) and are represented as mean and s.d.
from two biological samples each tested in duplicate. Levels of PLD1 mRNA were significantly higher in TMX2-28 cells than in MCF-7, 184, and 184AA2
cells (Po0.05). The same trend was apparent between TMX2-28 and 184A1 cells, but the means were not significantly different (P¼0.056).
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phoretic transfer cell and protocol (BioRad). Oestrogen receptor-a
mouse monoclonal antibody (NCL-ER-6F11, Nova Castra,
Newcastle, UK) was used at 1:100, and b-actin (Cell Signaling
Technology) at 1:1000.
Cell-cycle analysis
Cells were grown in culture medium containing charcoal/dextran-
treated FBS (reduced serum) for 48h for synchronisation and
harvested near 80% confluence. Adherent cell cultures were
harvested by trypsinisation, re-suspended in PBS, and fixed with
75% ethanol for 2h at 41C. Fixed cells were treated with 10mgml
 1
RNase A and DNA was stained with propidium iodine
(100mgml
 1) for 30min. Single cells (1 10
6cellsml
 1) were
analysed with the FACSCalibur and CellQuest Software (Becton
Dickinson, Franklin Lakes, NJ, USA). Cell-cycle analysis was
performed using ModFit LT 2.0 software (Verity Software House,
Topsham, ME, USA).
Statistics
The Mann–Whitney U-statistical test was used to determine the
association of mRNA levels for selected genes with tumours
expressing either basal CKs or ER. Student’s two-tailed t-tests were
used for planned comparisons between MCF-7 and TMX2-28 for
each cell-cycle stage, and for comparison of mRNA levels between
TMX2-28 and each of the four breast cell lines. Significance was set
at Pp0.05.
RESULTS
Characterisation of TMX2-28 cells
The TMX2-28 cell line was 1 of 28 clones derived from human
MCF-7 breast cancer cells grown in the presence of the anti-
oestrogen, tamoxifen, for 6 months (Fasco et al, 2003; Pentecost
et al, 2005). As shown in Figure 1A, TMX2-28 cells do not express
ERa mRNA or protein. Comparison between the cell-cycle
progression of the ER-negative TMX2-28 cells and the ER-positive
MCF-7 cells revealed increased mitotic activity of TMX2-28 cells
(Figure 1B). Significantly more TMX2-28 cells were in S and G2/M
phases (1.6 and 2.0 times greater) and fewer were in G0/G1 phase,
as compared to MCF-7. These data suggest that TMX2-28 cells
have lost G0/G1 regulation of the cell cycle, resulting in increased
cell division and proliferation. Furthermore, TMX2-28 cells are
more invasive than are MCF-7 cells (Gozgit et al, 2006), leading us
to characterise TMX2-28 as an aggressive ER-negative breast
cancer cell line.
Recent reports have shown that ER-negative tumours frequently
express the basal-like gene signature and are correlated with poor
clinical outcome (Perou et al, 2000; Sorlie et al, 2001; Abd El-
Rehim et al, 2004). Since TMX2-28 cells have lost expression of the
ER and show an aggressive phenotype, we examined the mRNA
levels of the seven CKs listed in Table 1 to determine if TMX2-28
cells express a similar basal-like CK gene signature. We found that
TMX2-28 cells display an altered CK mRNA expression profile
compared to MCF-7 cells; this profile is similar to the mixed basal/
luminal phenotype recently described for a subset of breast
carcinomas (Abd El-Rehim et al, 2004). TMX2-28 cells express
much higher levels of basal CK mRNAs (CKs 5, 14, and 17) than do
Table 1 Comparison of cytokeratin mRNA expression profile among
TMX2-28, MCF-7, and 184 HMEC cells
Basal cytokeratins
Cell line 5 14 17
TMX2-28 5 1100 0.67
MCF-7 0.007 4.6 0.019
184 HMEC 254 52991 689
Luminal cytokeratins
81 81 9 2 0
TMX2-28 633 1050 78 0.011
MCF-7 956 856 967 939
184 HMEC 30 54 o0.0001 o0.0001
Relative mRNA levels determined by real-time RT–PCR normalised to HPRT.
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Figure 2 Phospholipase D1 (PLD1) mRNA levels are highly expressed
in basal-like breast carcinomas. Total RNA was isolated from frozen
human–breast tumour specimens, and gene expression was determined
using real-time RT–PCR. An arbitrary cutoff point was used to select
tumours that expressed high levels of cytokeratin (CK5), CK17, and PLD1.
Phospholipase D1 mRNA levels were significantly higher in tumours that
expressed high levels of CK5 and/or 17 (Po0.01). Phospholipase D1
mRNA levels were not significantly higher in oestrogen receptor (ER)-
negative tumours (1–18 are ER positive, and 19–30 are ER negative,
P40.05, see text for details). Samples were tested two or three times; s.d.
represents variation between PCR experiments.
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sMCF-7 cells (Table 1). Luminal CKs 8 and 18 are similarly
expressed in TMX2-28 and MCF-7 cells; however, TMX2-28 cells
have lost expression of luminal CKs 19 and 20. Although TMX2-28
cells overexpress CKs 5, 14, and 17 compared to MCF-7 cells it is
important to note that TMX2-28 cells express much lower levels of
these basal CKs than do the 184 HMECs, which display a basal
phenotype.
To further examine the potential differences between TMX2-28
and MCF-7 cells, we compared the global gene expression of the
two cell lines using cDNA microarray analysis. cDNA microarray
comparison of TMX2-28 and MCF-7 cells resulted in 1402
differentially expressed transcripts (Supplementary Table 1). Two
hundred transcripts were upregulated, and 1202 were down-
regulated in TMX2-28 compared to MCF-7 cells. Using NetAffx
software (Liu et al, 2003), we sorted the 200 upregulated
transcripts by biological function, with specific attention on genes
involved in cell-cycle control and proliferation, and we found that
PLD1 was expressed at a level 2.1-fold higher in TMX2-28 cells
than in MCF-7 cells.
Using real-time RT–PCR, we found that PLD1 was over-
expressed by 10-fold in TMX2-28 cells compared to MCF-7
(Figure 1C). We also evaluated the expression of PLD1 in the non-
tumorigenic HMEC lines 184 (finite lifespan), 184A1 (immorta-
lised), and 184AA2 (immortalised, p53 null). We found that while
PLD1 was moderately expressed in these non-tumorigenic breast
cell lines, it was expressed significantly more in TMX2-28
(Figure 1C).
PLD1 mRNA expression in clinical breast tumours
To determine whether PLD1 gene expression correlates with either
the basal or luminal CKs and/or ER status in breast tumour tissue,
we isolated RNA from 30 frozen human–breast carcinomas and
evaluated gene expression by real-time RT–PCR. We used an
ER
Phospho-mTOR Ki67  Phospho-p70S6k
Phospho-Akt PLD1 CK17
Figure 4 Protein-expression profile of tumour specimen no. 22. The matching formalin-fixed, paraffin-embedded (FFPE) tissue for tumour specimen no.
22 (see Figure 2) was sectioned, and protein expression was determined by immunohistochemistry (IHC). The staining profile for this tumour demonstrates
that the phospholipase D1 (PLD1)/mammalian target of rapamycin (mTOR)/p70S6K pathway is active in cytokeratin (CK17)-positive tumour cells that are
negative for phospho-Akt and ER expression.
Figure 3 Phospholipase D1 (PLD1) expression in tissues from reduction mammoplasty. Phospholipase D1 shows moderate expression in tissue
specimens from reduction mammoplasty as determined by immunohistochemistry (IHC); a representative image of PLD1 staining is shown. Phospholipase
D1 immunoreactivity was concentrated in the outer basal/myoepithelial cell layer of the terminal ductal lobular units (TDLUs) of the breast. An enlarged
image of cells with a TDLU showing PLD1 expression in the outer basal/myoepithelial cell layer is shown on the right.
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(40.1 arbitrary units) and CK17 (40.002 arbitrary units). We
identified 11 tumours that expressed high-mRNA levels for either
CK5 and/or 17 (Figure 2). Of these 11 tumours, 8 expressed both
CKs 5 and 17, while 2 expressed only CK5, and 1 expressed only
CK17. Five of the 11 tumours that expressed either CK5 and/or 17
did not express luminal CKs 8/18, whereas the remaining six
tumours expressed a mixed basal/luminal CK expression profile
(data not shown). The levels of PLD1 mRNA were evaluated in the
30 frozen human–breast carcinomas. Phospholipase D1 mRNA
levels were significantly greater (40.25 arbitrary units) in tumours
that scored high for CKs 5 and/or 17 expression (Figure 2;
Po0.01). Next, we examined the relation between PLD1 expression
and ER status. Oestrogen receptor status was obtained from the
pathology reports that accompanied each tumour specimen.
Tumour specimens 1–18 are ER positive, and tumour specimens
19–30 are ER negative. Phospholipase D1 mRNA expression was
not correlated with ER status (P40.05).
We also evaluated the expression of PLD1 in tissues from
reduction mammoplasty. We found moderate PLD1 protein
expression in 4 of 10 tissues from reduction mammoplasty. An
example of protein expression in a tissue specimen from reductive
mammoplasty is shown in Figure 3. The other six tissues from
reductive mammoplasty showed weak staining (baseline level
expression) for PLD1. Interestingly, PLD1 protein was detected
specifically in the outer basal/myoepithelial cell layer within the
Table 2 Immunohistochemical analysis of PLD1 in human breast carcinomas
Tumour category Tumour ID PLD1 Phospho-Akt Phospho-mTOR CK5 CK17 ER Grade
PLD1 and phospho-Akt overexpressed 1 3 2 1 0 0 Pos II
2 2 2 1 0 3 Neg III
3 2 2 3 0 0 Pos III
4 2 2 2 0 3 Pos III
5 2 2 1 0 0 Pos I
PLD1 overexpressed and phospho-Akt low or negative 6 3 1 3 0 0 Neg III
7 2 1 2 0 0 Pos II
8 2 0 2 3 0 Neg III
9 2 0 2 0 0 Pos III
10 2 0 2 0 0 Neg I
PLD1 positive (low) 11 1 2 3 0 0 Pos II
12 1 2 3 0 0 Pos II
13 1 2 2 0 0 Pos I
14 1 2 1 0 0 Pos II
15 1 1 2 0 0 Unk I
16 1 1 2 0 0 Pos II
17 1 1 1 0 0 Unk I
18 1 1 0 0 0 Pos III
19 1 1 3 0 0 Unk II
20 1 1 1 0 0 Pos II
21 1 0 0 0 0 Pos III
22 1 0 3 0 0 Pos III
23 1 0 1 0 0 Neg III
24 1 0 3 0 0 Neg II
25 1 0 3 0 0 Pos III
26 1 0 3 0 0 Pos II
27 1 ND ND 0 0 Neg Unk
PLD1 negative 28 0 2 2 0 0 Pos II
29 0 2 0 0 0 Pos II
30 0 2 2 0 0 Neg III
31 0 1 3 3 3 Neg III
32 0 1 1 0 0 Pos III
33 0 1 2 0 0 Pos II
34 0 0 2 0 0 Pos II
35 0 0 2 0 0 Pos I
36 0 0 2 0 0 Pos I
37 0 0 2 0 0 Neg II
38 0 0 0 0 0 Pos III
39 0 0 0 0 0 Neg III
40 0 0 0 0 0 Pos III
41 0 0 0 0 0 Pos II
42 0 0 0 0 0 Pos II
PLD1 not determined 43 ND 0 1 0 0 Pos I
44 ND ND ND 0 0 Neg III
45 ND 1 3 0 0 Pos II
46 ND 1 0 0 0 Pos II
ND¼expression not detected due to inadequate tissue represented on TMA; Unk¼ER status unknown. IHC was scored on a scale of 0–3, where 0¼no staining, 1¼weak or
basal level, 2¼moderate, and 3¼strong. A score of moderate or strong expression is considered overexpressed.
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sterminal ductal lobular units of the breast (see Figure 3),
suggesting a potential role for PLD1 in the basal/myoepithelial
cells, as opposed to the luminal cells.
Immunohistochemical analysis of PLD1, phospho-Akt and
phospho-mTOR in clinical breast carcinomas
Akt activity is frequently overexpressed in HER2-positive breast
tumours (Tokunaga et al, 2006), and basal-like tumours tend to
have low HER2 levels (Perou et al, 2000; Nielsen et al, 2004). We
have found that PLD1 mRNA levels are significantly higher in
basal-like tumours (Figure 2); therefore, we reasoned that PLD1
may be inversely expressed with phospho-Akt in breast tumours
with basal-like features. We began by evaluating the expression
profile of a breast tumour specimen that had high-PLD1 mRNA
levels (shown in Figure 2). As shown in Figure 4, tumour specimen
no. 22 is ER negative, expresses the basal marker CK17, and
is PLD1 positive. Cancer cells in this tumour are negative for
phospho-Akt, but show positive cytoplasmic expression for
activated phospho-mTOR and positive nuclear phosphorylated
expression for the downstream mTOR effector, p70S6k. This
particular breast tumour represents a case in which PLD1 and
phospho-Akt are inversely expressed, and the PLD1/mTOR/p70S6k
pathway is active in the cancer cells. Figure 4 also illustrates that
this tumour shows high expression for the proliferation marker,
Ki67; the pathology report indicated that this is a high-grade
tumour. This tumour represents a type that does not express
targets for either anti-hormone or -HER2 therapies. Therefore,
identification of new molecular pathways such as PLD1/PA/mTOR
signalling that are constitutively active in such types of tumours
may be useful in selecting alternative targeted therapies.
To evaluate further the relationship of PLD1 with phospho-Akt,
we used TMA and IHC technology to examine 42 breast
carcinomas. The design of the TMA is described in the Materials
and Methods section. Oestrogen receptor expression was deter-
mined from the pathology reports that accompanied each tumour
specimen, and the expression of PLD1, phospho-Akt, phospho-
mTOR, and CKs 5/17 was evaluated by IHC analysis (Table 2).
Phospholipase D1 was expressed in 27 of the 42 breast tumours.
Seventeen tumours had a basal level of PLD1 expression (score of
1), whereas the other 10 tumours overexpressed PLD1 (score of 2
or 3). Phospholipase D1 was overexpressed in 6 of the 28 ER-
positive tumours and in 4 of the 11 ER-negative cases. Although
only four tumours scored positive for CK5 and/or CK17
expression, it is interesting to note that PLD1 was overexpressed
in 3 of the 4 CK5/17-positive cases, the basal-like CK-expression
pattern. Of the 10 tumours that overexpressed PLD1, 5 were
negative for phospho-Akt expression, and importantly, these 5
PLD1-positive tumours overexpressed phospho-mTOR (Table 2,
tumours 6–10). Representative images of a tumour that over-
expressed PLD1 and phospho-mTOR, but did not express
phospho-Akt, are shown in Figure 5A. These data indicate that
PLD1 may be activating the mTOR pathway in these tumours that
do not have constitutive phospho-Akt expression. Seven tumours
PLD1 Phospho-Akt Phospho-mTOR 
Figure 5 Phospholipase D1 (PLD1) and phospho-Akt are inversely expressed in a subset of breast carcinomas. Tissue microarrays (TMAs) were
constructed with archived formalin-fixed, paraffin-embedded (FFPE) breast carcinomas, and protein expression was determined by immunohistochemistry
(IHC). Representative photographs are shown: row (A), tumour cells show positive staining for PLD1, negative for phospho-Akt, but positive for phospho-
mammalian target of rapamycin (mTOR); row (B), PLD1 shows positive expression in stromal cells, but is negative in the tumour cells, whereas phospho-
Akt and -mTOR show positive expression in tumour cells; row (C), shows positive expression for PLD1, phospho-Akt, and phospho-mTOR.
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five of these tumours scored positive for phospho-mTOR.
Representative images of a tumour that stained negative for
PLD1 and positive for both phospho-Akt and phospho-mTOR are
shown in Figure 5B. Lastly, five tumour specimens overexpressed
both PLD1 and phospho-Akt, and two of these five tumours
overexpressed phospho-mTOR. An example of a tumour over-
expressing all three proteins is shown in Figure 5C. Interestingly, 6
of the 10 tumours that overexpressed PLD1 are grade 3 tumours,
and 5 of these tumours are among the 7 tumours that overexpress
PLD1 along with phospho-mTOR. These data suggest the
possibility that PLD1/mTOR signalling plays a role in the growth
of high-grade tumours; and a larger study evaluating the
expression of these proteins with tumour grade and patient
prognosis is clearly warranted.
DISCUSSION
Phospholipase D1 has been implicated in breast cancer tumor-
igenesis and has been proposed to play a role in oestrogen-
independent growth (Foster and Xu, 2003; Rodrik et al, 2005). Two
previous reports examined PLD activity and expression, both in a
relatively small number of breast cancers. Elevated PLD activity
was found in 17 out of 19 microsomal preparations from human
breast tumours as compared to microsomal preparations from
adjacent normal breast tissue (Uchida et al, 1997) and PLD mRNA
and protein levels were overexpressed in 14 of 17 breast cancer
tissues compared to normal (Noh et al, 2000). Our findings that
PLD1 is overexpressed in TMX2-28 breast cancer cells and in a
subset of breast tumours are consistent with the published data.
In this study, we are the first to demonstrate that the PLD1/
mTOR pathway is active in a subset of clinical breast carcinomas
that are negative for phospho-Akt. This finding is consistent with
results reported by Chen et al (2005) who showed that PLD1 and
phospho-Akt are inversely expressed in a subset of breast cancer
cell lines. Taken together, their study and ours suggest that an
alternative mTOR activation pathway is active in a subset of breast
tumours (see Figure 6 for model). Patients with tumours
expressing activated PLD1/mTOR signalling may be sensitive to
rapamycin-based therapies; however, it has been shown that high
levels of PLD1 confers rapamycin resistance in MDA-MB-231
breast cancer cells in vitro (Chen et al, 2003). Although this is an
important finding it is limited to cell lines and clinical trials
utilising phospho-Akt as well as PLD1 expression are needed to
understand the sensitivity of rapamycin-based therapies. We also
found that PLD1 and phospho-Akt are coexpressed in some breast
tumours, a fact which could complicate the utility of rapamycin-
based therapies, as patients expressing both proteins could differ
in sensitivity to mTOR inhibitors. We found that PLD1 was
expressed in six ER-positive tumours; four of these tumours
showed positive phospho-mTOR expression, and two were
negative for phospho-Akt expression. Therefore, it is plausible
that those patients with tumours positive for ER and PLD1 will
respond to combined anti-hormone and rapamycin-based thera-
pies; that combination has been successful in inhibiting the
proliferation of breast cancer cell lines (Boulay et al, 2005). Our
data also show that most basal-like tumours express PLD1, and it
has been shown that patients with these types of tumours suffer
from poor prognosis (Sorlie et al, 2001; Abd El-Rehim et al, 2004).
Although we limited our studies to the evaluation of PLD1 mRNA
and protein it is important to point out that PLD1 expression may
not always correlate with PLD1 activity. Therefore, it is plausible
that tumour cells with basal PLD1 mRNA/protein may still have
altered PLD1 enzyme activity. Furthermore, a second isoform of
PLD, PLD2, may play a role in the transformed phenotype (Foster
and Xu, 2003); however, in our study we limited the analysis to
PLD1.
Rapamycin-based therapies target mTOR and are in clinical
trials for various cancers including breast (Carraway and Hidalgo,
2004). Studies on breast cancer cell lines have revealed that the
rapamycin analogue CCI-779 was most effective in inhibiting
growth in cell lines that were ER-dependent, that overexpressed
HER-2 and/or had PTEN deletions, and that expressed high levels
of activated Akt (Carraway and Hidalgo, 2004). Others have
suggested that patients with breast tumours displaying aberrant
PI3K/Akt/mTOR signalling will benefit the most from rapamycin-
based therapies, because tumour cells that have abnormal
expression in the PI3K/Akt/mTOR pathway may depend on this
pathway for growth, and therefore may be sensitive to mTOR
inhibitors (Hidalgo and Rowinsky, 2000; Carraway and Hidalgo,
2004; Thomas, 2006). Data from our study identify an additional
subset of patients with tumours that overexpress PLD1 and
phospho-mTOR, but do not express constitutive levels of
phospho-Akt.
In this report, we have used the MCF-7-derived cell line, TMX2-
28, as a model to study ER-negative breast cancer. Gene-expression
studies identified the overexpression of PLD1 in TMX2-28 cells.
We are the first to report that PLD1 is highly expressed in some
phospho-Akt-negative clinical breast tumours. These data support
the studies by Chen and colleagues that suggest the presence of an
alternative mTOR activation pathway in breast cancer cell lines
RTK
GTPases/PKC
PI3K
PTEN
Other
effectors
Ribosome
biogenesis
Translation
initiation
PIP2 PIP3 PLD1
PA
Akt
mTOR
p70S6K 4EBP1
Figure 6 Model of alternative mammalian target of rapamycin (mTOR)
Activation by PLD1 in breast cancer. Receptor tyrosine kinases (RTKs)
activate several downstream signals including small GTPases, PKCa, and
PI3K. Phospholipase D1 (PLD1) is activated, by either members of the small
GTPase family or by PKCa, and is dependent on phosphatidylinositol-4,5-
bis-phosphate (PIP2) to generate phosphatidic acid (PA), whereas Akt
requires PIP3 for localisation to the plasma membrane and activation.
Phosphatidic acid or phosphorylated Akt activates the protein kinase
mTOR, which phosphorylates its downstream effectors p70S6K and 4E-BP1,
thereby promoting cell growth and proliferation (adapted from Foster
and Xu, 2003).
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swith high-PLD1 activity and relatively low-phospho-Akt levels.
Phospholipase D1 tends to be overexpressed in tumours that
express high levels of CKs 5/17, markers of basal-like tumours, and
others have shown basal-like tumours are frequently associated
with poor prognosis. On the basis of these studies we speculate
that PLD1 may serve as a biomarker for selecting patients for
rapamycin-based therapies; a larger follow-up study to evaluate the
clinical utility of PLD1 is clearly warranted.
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